Evidence map›Paper›PMID 34477817›Full record

ArticleBlood advances2021

Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms.

Miriam Elbracht, Robert Meyer, Kim Kricheldorf, Deniz Gezer, Thomas Eggermann, Beate Betz, Ingo Kurth, Lino L Teichmann, Tim H Brümmendorf, Ulrich Germing and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. JAK2Leukemia · 2026
    Article
  2. Article
  3. Review
  4. Evaluation of theHaematologica · 2024
    Article
  5. Article
  6. Article
  7. Molecular Pathogenesis of Myeloproliferative Neoplasms.Current hematologic malignancy reports · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Miriam ElbrachtInstitute of Human Genetics, Medical Faculty, RWTH Aachen University, Aachen, Germany.ORCID 0000-0001-5088-1369
Robert MeyerInstitute of Human Genetics, Medical Faculty, RWTH Aachen University, Aachen, Germany.ORCID 0000-0002-5693-2216
Kim KricheldorfDepartment of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.ORCID 0000-0003-3102-2221
Deniz GezerDepartment of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Thomas EggermannInstitute of Human Genetics, Medical Faculty, RWTH Aachen University, Aachen, Germany.ORCID 0000-0002-8419-0264
Beate BetzInstitute for Human Genetics, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Ingo KurthInstitute of Human Genetics, Medical Faculty, RWTH Aachen University, Aachen, Germany.ORCID 0000-0002-5642-8378
Lino L TeichmannDepartment of Hematology and Oncology, University Hospital Bonn, Bonn, Germany; and.
Tim H BrümmendorfDepartment of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.ORCID 0000-0002-9677-3723
Ulrich GermingDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Susanne IsfortDepartment of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Steffen KoschmiederDepartment of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.ORCID 0000-0002-1011-8171
RWTH Aachen University · DEDüsseldorf University Hospital · DEUniversity Hospital Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The molecular causes of myeloproliferative neoplasms (MPNs) have not yet been fully elucidated. Approximately 7% to 8% of the patients carry predisposing genetic germline variants that lead to driver mutations, which enhance JAK-STAT signaling. To identify additional predisposing genetic germline variants, we performed whole-exome sequencing in 5 families, each with parent-child or sibling pairs affected by MPNs and carrying the somatic JAK2 V617F mutation. In 4 families, we detected rare germline variants in known tumor predisposition genes of the DNA repair pathway, including the highly penetrant BRCA1 and BRCA2 genes. The identification of an underlying hereditary tumor predisposition is of major relevance for the individual patients as well as for their families in the context of therapeutic options and preventive care. Two patients with essential thrombocythemia or polycythemia vera experienced progression to acute myeloid leukemia, which may suggest a high risk of leukemic transformation in these familial MPNs. Our study demonstrates the relevance of genetic germline diagnostics in elucidating the causes of MPNs and suggests novel therapeutic options (eg, PARP inhibitors) in MPNs. Furthermore, we uncover a broader tumor spectrum upon the detection of a germline mutation in genes of the DNA repair pathway.

Indexed as

Leukemia, Myeloid, AcuteMyeloproliferative DisordersBRCA1 ProteinDNA RepairGerm CellsHumansJanus Kinase 2BRCA1 ProteinBRCA1 protein, humanJanus Kinase 2

Identifiers

PMID34477817
PMCPMC8525218
OpenAlexW3198888604

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.